Federal Register / Vol. 74, No. 192 / Tuesday, October 6, 2009 / Notices 51293 

line/phone line to learn about possible 

modifications before coming to the 

meeting. 

Agenda: On December 8, 2009, the 

committee will discuss safety 

considerations related to FDA-approved 

gadolinium-based contrast agents used 

with magnetic resonance imaging (MRI) 

scans. An MRI is a medical imaging 

technique that does not require x-rays. 

These scans outline the internal body 

structures such as organs and other soft 

tissues. Contrast agents are substances 

injected into the body before MRI scans, 

helping doctors to better see and 

interpret MRI findings. FDA approved 

gadolinium-based contrast agents 

include: gadobenate dimeglumine 

(MULTIHANCE), gadodiamide 

(OMNISCAN), gadopentetate 

dimeglumine (MAGNEVIST), 

gadoteridol (PROHANCE), 

gadoversetamide (OPTIMARK), 

gadoxetate disodium (EOVIST), and 

gadofosveset (ABLAVAR, previously 

known as VASOVIST). 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before November 23, 2009. 

Oral presentations from the public will 

be scheduled between approximately 1 

p.m. to 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before November 13, 2009. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

November 16, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Elaine 

Ferguson at least 7 days in advance of 

the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: October 1, 2009. 

David Horowitz, 

Assistant Commissioner for Policy. 

[FR Doc. E9–24014 Filed 10–5–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; International Collaborations 

in Infectious Disease Research (ICIDR). 

Date: November 2, 2009. 

Time: 10:30 a.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817 

(Telephone Conference Call). 

Contact Person: Gary S. Madonna, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, Bethesda, MD 20892, (301) 

496–3528, gm12w@nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; International Collaborations 

in Infectious Disease Research (ICIDR). 

Date: November 4, 2009. 

Time: 10:30 a.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817 

(Telephone Conference Call). 

Contact Person: Gary S. Madonna, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, Bethesda, MD 20892, (301) 

496–3528, gm12w@nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; International Collaborations 

in Infectious Disease Research (ICIDR). 

Date: November 6, 2009. 

Time: 10:30 a.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817 

(Telephone Conference Call). 

Contact Person: Gary S. Madonna, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, Bethesda, MD 20892, (301) 

496–3528, gm12w@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 29, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23979 Filed 10–5–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 


jlentini on DSKJ8SOYB1PROD with NOTICES
51294 Federal Register / Vol. 74, No. 192 / Tuesday, October 6, 2009 / Notices 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HIV Research Support. 

Date: October 28, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Eric Lorenzo, PhD, 

Scientific Review Officer, Scientific Review 

Program, DEA/NIAID/NIH/DHHS, Room 

2217, 6700B Rockledge Drive, MSC–7616, 

Bethesda, MD 20892–7616. 301–496–2550. 

lorenzoe@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 29, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23978 Filed 10–5–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel. Brain 

Dopamine. 

Date: October 29, 2009. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

2C212, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Alicja L Markowska, PhD, 

DSC, Scientific Review Officer, Scientific 

Review Branch, National Institute on Aging, 

7201 Wisconsin Avenue, Suite 2C212, 

Bethesda, MD 20892. 301–496–9666. 

markowsa@nia.nih.gov. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel. Cardiac 

Progenitor Cells and Aging. 

Date: November 10, 2009. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

2C212, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Elaine Lewis, PhD, 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Aging, Gateway 

Building, Suite 2C212, MSC–9205, 7201 

Wisconsin Avenue, Bethesda, MD 20892. 

301–402–7707. elainelewis@nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: September 29, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23977 Filed 10–5–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel, 

Building Translational Research in 

Integrative Behavioral Science. 

Date: November 4, 2009. 

Time: 3 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call.) 

Contact Person: Rebecca C Steiner, PhD, 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd, Room 6149, MSC 9608, 

Bethesda, MD 20892–9608. 301–443–4525. 

steinerr@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: September 29, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23976 Filed 10–5–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of an Interagency Autism 

Coordinating Committee (IACC) 

meeting. 

The purpose of the IACC meeting is 

to discuss recommendations for the 

annual update of the IACC Strategic 

Plan for Autism Spectrum Disorders 

Research. The meeting will be open to 

the public and will be accessible by 

webcast and conference call. 

Name of Committee: Interagency Autism 

Coordinating Committee (IACC). 

Type of meeting: Open. 

Date: October 23, 2009. 

Time: 9 a.m. to 5 p.m.* Eastern Time— 

*Approximate end time. 

Agenda: A presentation by a panel of 

parents of children with autism; a 

presentation on Applied Behavioral Analysis 

by Dr. Tony Charman; and discussion of 

recommendations for updating the IACC 

Strategic Plan for Autism Spectrum Disorders 

Research. 

Place: The National Institutes of Health, 

Main Campus, William H. Natcher 

Conference Center, 45 Center Drive, 

Conference Rooms E1/E2, Bethesda, MD 

20892. 

Webcast Live: http://videocast.nih.gov/. 

Conference Call Access: Dial: 888–455– 

2920; Access code: 3132846. 

Cost: The meeting is free and open to the 

public. 

Registration: http:// 

www.acclaroresearch.com/oarc/10–23– 

09_IACC/. Pre-registration is recommended 

to expedite check-in. Seating in the meeting 

room is limited to room capacity and on a 

first come, first served basis. 

Access: Metro accessible—Red Line— 

Medical Center Metro Station. 


jlentini on DSKJ8SOYB1PROD with NOTICES